# reload+after+2024-01-21 04:48:04.003753
address1§61 North Beacon Street
address2§4th Floor
city§Boston
state§MA
zip§02134
country§United States
phone§857 529 8300
website§https://www.x4pharma.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.
fullTimeEmployees§86
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Paula  Ragan Ph.D.', 'age': 53, 'title': 'CEO, President & Director', 'yearBorn': 1970, 'fiscalYear': 2022, 'totalPay': 963580, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Adam S. Mostafa', 'age': 43, 'title': 'CFO, Treasurer & Corporate Secretary', 'yearBorn': 1980, 'fiscalYear': 2022, 'totalPay': 699182, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Mary  DiBiase Ph.D.', 'age': 62, 'title': 'Chief Operating Officer', 'yearBorn': 1961, 'fiscalYear': 2022, 'totalPay': 661588, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Richard  Peters M.D., Ph.D.', 'age': 60, 'title': 'Founder', 'yearBorn': 1963, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Renato T. Skerlj Ph.D.', 'title': 'Founder', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Keith T. Flaherty M.D.', 'age': 52, 'title': 'Founder & Member of Corporate Advisory Board', 'yearBorn': 1971, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Arthur  Taveras Ph.D.', 'age': 59, 'title': 'Chief Scientific Officer', 'yearBorn': 1964, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Glenn  Schulman M.P.H., Pharm. D., Pharm.D.', 'title': 'Vice President of Investor Relations & Corporate Communications', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Robert David Arbeit', 'age': 75, 'title': 'Senior Vice President of Clinical Development and Translational Research', 'yearBorn': 1948, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Mark  Baldry M.B.A.', 'age': 59, 'title': 'Chief Commercial Officer', 'yearBorn': 1964, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§9
boardRisk§6
compensationRisk§8
shareHolderRightsRisk§8
overallRisk§8
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§0.376
currency§USD
dateShortInterest§1702598400
forwardEps§-0.42
exchange§NCM
quoteType§EQUITY
shortName§X4 Pharmaceuticals, Inc.
longName§X4 Pharmaceuticals, Inc.
firstTradeDateEpochUtc§1510842600
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§08bc365d-9086-31a6-8c95-0c974c46c923
gmtOffSetMilliseconds§-18000000
targetHighPrice§5.0
targetLowPrice§1.0
targetMeanPrice§3.26
targetMedianPrice§3.0
recommendationMean§2.0
recommendationKey§buy
numberOfAnalystOpinions§7
quickRatio§5.587
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
